Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico

References

• O’Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27:95-112
   PubMed Web of Science ®Google Scholar
• IASP. Task force ont: classification of chronic pain, 2nd edn. Seattle, WA: IASP Press, 1994
   Google Scholar
• Hartemann A, Attal N, Bouhassira D, et al. Painful diabetic neuropathy: diagnosis and management. Diabetes Metab 2011;37(5):377-88
   Google Scholar
• Beard SM, McCrink L, Le TK, et al. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin 2008;24:385-99
   PubMed Web of Science ®Google Scholar
• Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008;9:660-74
   PubMed Web of Science ®Google Scholar
• Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev 2008;24:52-7
   PubMed Web of Science ®Google Scholar
• Hartsfield CL, Korner EJ, Ellis JL, et al. Painful diabetic peripheral neuropathy in a managed care setting: patient identification, prevalence estimates, and pharmacy utilization patterns. Popul Health Manag 2008;11:317-28
   PubMed Web of Science ®Google Scholar
• Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007;8:50-62
   PubMed Web of Science ®Google Scholar
• Jensen TS, Backonja MM, Hernández Jiménez S, et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 2006;3:108-19
   PubMedGoogle Scholar
• Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35:206-13
   PubMed Web of Science ®Google Scholar
• Doth AH, Hansson PT, Jensen MP, et al. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain 2010;149:338-44
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005;30:374-85
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Woehl A, et al. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006;49:2272-80
   PubMed Web of Science ®Google Scholar
• Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 2006;20:26-33
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006;7:892-900
   PubMed Web of Science ®Google Scholar
• Ritzwoller DP, Ellis JL, Korner EJ, et al. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting. Curr Med Res Opin 2009;25:1319-28
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Malone DC, Panarites CJ, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010;11:360-8
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
   PubMed Web of Science ®Google Scholar
• Bril V, England JD, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy–report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation. Muscle Nerve 2011;43:910-7
   PubMed Web of Science ®Google Scholar
• Centre for Clinical Practice at NICE. NICE clinical guideline 96. Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings of neuropathic pain in adults in non-specialist settings. National Institute for Health and Clinical Excellence, London 2010
   Google Scholar
• Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009;9:6
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18
   PubMed Web of Science ®Google Scholar
• Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20
   PubMed Web of Science ®Google Scholar
• Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007;29:2536-46
   PubMed Web of Science ®Google Scholar
• Dictionary of Pharmaceutical Specialties DEF-55 PLM 2009. Editorial Thompson Mexico, Mexico City, Mexico 2009
   Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:22-33
   PubMed Web of Science ®Google Scholar
• Kobelt G. Health economics: an introduction to economic evaluation. 2nd edn. London, UK: Office for Health Economics, 2002;1:9-24
   Google Scholar
• Drummond MF, Sculpher MJ, Torrance G, et al. Methods for the economic evaluation of health care programmes. 3rd Edn. UK: Oxford University Press, 2005
   Google Scholar
• Fox-Rushby JA, Griffith GL, Ross JR, et al. The clinical and cost-effectiveness of different treatment pathways for neuropathic pain [NP]. NIHR Health Technology Assessment (HTA) programme, ref. 05/30/03. 2011. In press
   Google Scholar
• Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain 2006;7:399-407
   Google Scholar
• O’Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics 2008;26:1045-64
   PubMed Web of Science ®Google Scholar
• Consejo de Salubridad General. Guía para la conducción de estudios de evaluación económica para la actualización del Cuadro Básico de Insumos del Sector Salud en México. México, DF, Agosto 2008. Available at: http://www.csg.salud.gob.mx/descargas/pdfs/cuadro_basico/GUxA_EVAL_ECON25082008_2_ech.pdf
   Google Scholar
• Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain 2006;7:119-28
   PubMed Web of Science ®Google Scholar
• O’Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc 2007;55:1176-84
   PubMed Web of Science ®Google Scholar
• Portal de transparencia del Instituto Mexicano del Seguro Social. Available at: transparencia.imss.gob.mx. Accessed January 27, 2011
   Google Scholar
• Portal del sistema electrónico de compras gubernamentales. Available at: www.compranet.gob.mx. Accessed January 31, 2011
   Google Scholar
• Listado de costos unitarios por nivel de atención en el Instituto Mexicano del Seguro Social. Diario Oficial de la Federación. Martes 18 de mayo de 2010
   Google Scholar
• Banco de México website. Available at: www.banxico.org.mx/indicadores/fix.html. Accessed February 7, 2011
   Google Scholar
• Arezzo JC, Rosenstock J, Lamoreaux L, et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008;8:33
   PubMed Web of Science ®Google Scholar
• Tölle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008;12:203-13
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research. Lyrica (pregabalin) capsules. Company: Pfizer Global Research & Development. Application no.: 021446. Approval date: 12/30/2004 [online]. Available at: www.fda.gov/cder/foi/nda/2004/021446_LyricaTOC.htm. Accessed March 5, 2007
   Google Scholar
• Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-63
   PubMed Web of Science ®Google Scholar
• Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-60
   PubMed Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63:2104-10
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-38
   PubMed Web of Science ®Google Scholar
• Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003;25:81-104
   PubMed Web of Science ®Google Scholar
• Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999;66:251-2
   PubMed Web of Science ®Google Scholar
• Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis 2001;3:53-62
   PubMedGoogle Scholar
• Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Modelling methods for health economic evaluation. New York: Oxford University Press, 2006
   Google Scholar
• International Monetary Fund. World Economic Outlook Database. IMF, Washington D.C., USA. October 2010
   Google Scholar
• Tarride JE, Gordon A, Vera-Llonch M, et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther 2006;28:1922-34
   PubMed Web of Science ®Google Scholar
• Rodríguez MJ, Díaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007;23:2585-96
   PubMed Web of Science ®Google Scholar
• Zhao FL, Yue M, Yang H, et al. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care 2011;49:267-72
   PubMed Web of Science ®Google Scholar
• WHO Commission on Macroeconomics Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2001
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134
   PubMed Web of Science ®Google Scholar
• Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472
   PubMed Web of Science ®Google Scholar
• Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008;61:455-63
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Clarke MJ, Wordsworth S, et al. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Pract 2009;63:841-54
   PubMed Web of Science ®Google Scholar
• General Health Council. Health Sector’s Formulary and Catalogue of Medication 2010. http://www.csg.salud.gob.mx/. Accessed August 29, 2011
   Google Scholar
• Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008;31:1448-54
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38
   PubMedGoogle Scholar